An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A big change is arriving in operating rooms: surgeons are starting to see patients on GLP-1 drugs more often, and that's changing how they plan and manage surgeries. The American College of Surgeons has put out guidance because these medicines — which people take for weight loss or diabetes — can affect things like wound healing, risk of infection, and how patients handle anesthesia. In short: surgeons need to know when a patient is taking a GLP-1 drug and may alter timing or monitoring around operations. GLP-1 drugs (short for glucagon-like peptide-1 receptor agonists) are pills or injections that act like a natural gut hormone. That hormone tells your brain you’re full and slows how fast your stomach empties. Medications in this class include widely known names used for diabetes and weight loss. They reduce appetite, help people lose weight, and lower blood sugar. Because they change digestion and metabolism, they can also change how the body responds to the stress of surgery. The guidance summarizes what surgeons and hospitals are seeing and what the evidence so far says. Much of the research comes from clinical observations and some studies, but not a huge number of randomized trials specifically about surgery. Reported issues include nausea, vomiting, and slower stomach emptying that can raise the risk of aspiration (breathing stomach contents into the lungs) during anesthesia. There are also concerns that reduced food intake and metabolic changes might affect wound healing or immune function after major procedures, though firm proof is limited. Where data are thin, the college errs on the side of caution and suggests practical steps like asking about GLP-1 use, considering short-term pauses before some surgeries, and watching patients closely afterward. This matters because a lot more people are now taking GLP-1 drugs for weight loss or diabetes, including younger and healthier patients who might still need surgery someday. If you’re having an operation, knowing whether you take one of these drugs helps your surgical team reduce avoidable risks. For patients, it means being prepared to tell your surgeon about these medications and follow any instructions about stopping them temporarily. For clinicians, it means reviewing hospital policies, adjusting anesthesia plans, and educating staff so patient care is safer. There are important caveats. Evidence is still evolving, so recommendations can change as better studies come out. Stopping a GLP-1 suddenly can lead to changes in blood sugar or return of appetite, which matters for people with diabetes. Not everyone on these drugs will have problems, and the balance of risks and benefits depends on the type of surgery and the patient’s health. These medications are prescription drugs — you should not stop or start them without talking to the doctor who prescribed them and your surgeon. Bottom line: GLP-1 drugs are common enough now that surgeons and anesthesiologists are updating how they manage patients, and anyone taking these medicines should make sure their surgical team knows about them well before the operation.
Source: The American College of Surgeons